Newsletters and more news updates

The latest newsletter (Spring ’20) is downloadable via this link (click link or right click and save as…).

David Casley, Prospect Publicity 07860 369064; Email



New guidance on active surveillance

New best-practice guidelines for doctors offering active surveillance have been published, as NICE recognise the procedure as being on a par with surgery and radiotherapy for men with low-risk localised PCa (May ’19). More here. And Prostate Cancer UK run a monthly group chat from men on active surveillance who want to share experiences and ask questions about the treatment. The group chat is on the second Tuesday of the month (7-8pm). Join the chat here.

At-home urine test created

A PCa test which can be carried out at home has been developed by university experts. Medics hope patients can receive an earlier and more accurate diagnosis by providing a urine sample. The test has been developed further so urine samples can be collected at home (Nov ’19). See more here. And scientists have created another urine test for PCa after trials on 155 men in Bristol (2016). See here

Anti-fatigue app approved

Untire has become the first Cancer-Related Fatigue (CRF) app to be approved by the NHS, and is now available to download for free via the NHS apps library. It aims to tackle CRF, one of the most common side effects of cancer and its treatment (Aug ’19). See more at

New hope for men whose cancer has spread

US clinical trials are likely to lead to approval of a new class of life-extending treatment options for men with metastatic hormone-sensitive PCa. This refers to men whose cancer has spread outside of the prostate and who are responsive to testosterone-lowering agents (July ’19). See more here

Jab “game changer’

A radical new treatment for PCa in which tumour injections boost the immune system to kill malignant cells has been hailed as a potential ‘game-changer’ (Dec ’18).  See here

Boost in prostate cases

Hospitals are treating more PCa cases, partly thanks to celebrities raising awareness of the disease by speaking out about their own experiences, says the NHS head. Simon Stevens thanked broadcasters Bill Turnbull and Stephen Fry for urging men to seek help (Oct ’18). See here.

Loved ones survey results

Cancer UK has published a summary of the key findings after a survey for partners and family members of men with PCa. Just under 400 people completed it. The charity asks that the summary, not a full detailed report, should not be shared or publicised, and it thanked those who helped with this work (Apr ’19).

Abiraterone ‘success’

One of the largest clinical trials for PCa has given “powerful results”, say UK researchers. Abiraterone, when used for treating prostate cancer that has spread, was found to save lives when offered earlier (June ’17). See and here.

Thousands of PCa patients could be spared surgery as experts create a tool that calculates their risk of dying from the disease with 90 per cent accuracy (Mar ’18). See here

Some treatment ‘unnecessary’

Thousands of men with PCa get risky treatment they don’t need. New approaches could curb that, it’s claimed (Nov ’17). See here And fhousands of PCa patients could be spared surgery as experts create a tool that calculates their risk of dying from the disease with 90 per cent accuracy (Mar ’18). See here

Isotope could be game-changer

A new brachytherapy isotope, Cesium-131, could be a game-changer, a US study indicates (Aug ’17). See here

Remarkable results claimed for nuclear medicine treatment

Remarkable results are claimed for an experimental treatment in Australia for advanced PCa patients who had exhausted all their options. It is a disruptive technology in the field of nuclear medicine, pioneered in Germany (Aug ’17). See here

New hope for advanced patients

Scientists have developed a blood test that could pick out which men with advanced PCa would benefit from a new drug treatment. The test detects cancer DNA, helping doctors check if precision drugs are working. Cancer Research UK said the test could “greatly improve survival”, but added that larger studies are needed to confirm if it is reliable. (Jun ’17). See here

New treatment to be tried out

After a pilot study, an associate Australian professor is to lead a trial of 200 patients with nuclear medicine treatment – what he believes could be a game-changer in the treatment of advanced PCa (July ’17). See here

Ignorance over newer tests

Half of urologists are unaware of newer, more sensitive biomarker tests for detecting prostate cancer, according to a worldwide survey of 300 mainly European specialists. The new tests reduce the need for biopsies (July ’17). See here

Defeating therapy resistance

A new US study sheds light on a signalling circuit in cells that drives therapy resistance in prostate cancer. Targeting the components of this circuit suppresses advanced cancer development. See here.

Laser treatment success

Surgeons described a new treatment for early stage PCa as “truly transformative”. The approach, tested in Europe, uses lasers and a drug made from deep-sea bacteria to kill tumours, without severe side effects. See here.

PSA test row

PSA tests may be unnecessary, the Academy of Medical Royal Colleges reported (Oct ’16). But Prostate Cancer UK says they are still the best first step until a more robust one suitable for a screening programme is devised. Several Prospect members wrote to the BBC or their MP about the situation. See here. And crowdfunding donations were successfully sought for a new non-invasive and affordable diagnostic test for the early detection of this cancer. See here

World first hailed

Scientists in Belfast claim a major breakthrough in PCa treatment. It is hoped the new discovery, hailed a world first, could help stop the spread of the disease and prevent relapses. Researchers have found that combining hormone therapy with a new drug, OCT1002, can improve treatment effectiveness. See here.

Drug targets tumours

A radioactive drug, which behaves like the substance used to kill Russian ex-spy Alexander Litvinenko, could be used to treat PCa patients. It targets tumours that have spread to the bones and has been approved by NICE. See here

Early detection claimed

Scientists at Israel’s Weizmann Institute might have found a PCa cure, at least if it’s caught early. See here.

New diagnosis tool; Zytiga affordable

A new risk assessment tool for GPs is set to revolutionise prostate cancer diagnosis. See here. And NICE has agreed that abiraterone (Zytiga) is affordable after a lower price was agreed with the makers. See here.

More accurate predictions?

Patients might be offered a more accurate prediction of their prostate cancer risk with a novel method developed by Cambridge University researchers. See here

Biopsies may be ‘out’

Urologists are committed to rolling out diagnostic use of the new MRI scans once their benefits are officially confirmed. The scans make it possible to rule out the need for a biopsy in many men who don’t have a clinically significant PCa. See here. Latest on this here. And US researchers have identified a marker of aggressive prostate cancer. See here

Back to top